BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...
KTVF on MSN2d
Health Watch: 10 years of TAVR; The life-changing heart procedure keeping Alaskans strongA decade after bringing Transcatheter Aortic Valve Replacement (TAVR) to Alaska, doctors at Providence Alaska Medical Center ...
The “passive” notification led to more patients with severe AS undergoing valve replacement, but more can be done still.
MedPage Today on MSN1d
Embattled TAVR Device Myval Meets Expectations in Trial, but Trouble Still AheadPitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices ...
Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...
Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...
MedPage Today on MSN6d
Evolut Low Risk TAVR Still Chugging Along, Now Halfway to Trial's Finish LineCHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at ...
Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...
JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.
Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.
Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback